CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Combining radiotherapy with CAR-T cell therapy for solid tumors: Challenges, mechanisms, and future directions.
Combining radiotherapy with CAR-T cell therapy for solid tumors: Challenges, mechanisms, and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法在治疗血液系统恶性肿瘤方面取得了显著成功。但与其对血液系统肿瘤的疗效相比,CAR-T 细胞疗法在实体瘤中的应用仍面临多项挑战。放射治疗是实体瘤治疗的重要组成部分,近期因其免疫调节作用而受到广泛关注。放疗联合治疗可能克服CAR-T 细胞疗法用于实体瘤时的局限。本综述讨论放疗联合CAR-T 细胞疗法的理论基础,以及相关临床前和临床研究进展。此外,本文探讨联合应用这两种疗法时需要考虑的关键因素,包括放疗剂量、方式、类型以及联合治疗的时机和给药安排。本综述为未来研究方向提供新视角,并指出仍待解决的关键问题。
Chimeric antigen receptor (CAR)-T cell therapy has achieved significant success in treating hematological malignancies.
However, compared to its efficacy against hematologic cancers, the application of CAR-T cell therapy for solid tumors still faces several challenges. Radiotherapy, an important component in the treatment of solid tumors, has recently attracted widespread attention because of its immunomodulatory effects. Combined radiotherapy may overcome the limitations of CAR-T cell therapy for solid tumors. This review discusses the theoretical foundations of combined radiation therapy and CAR-T cell therapy, along with preclinical and clinical research progress.
Additionally, this study provides an innovative exploration of key factors to be considered when combining these two therapies. These factors include radiation dose, mode, radiation type, and timing and scheduling of the combined treatment. This review offers new perspectives on future research directions and highlights critical issues that remain to be addressed.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。